GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Clinical trials for GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a common heart drug boost cancer treatment? a trial puts propranolol to the test
Disease control Not yet recruitingThis trial is investigating whether adding the beta-blocker propranolol to standard chemotherapy and immunotherapy before surgery can improve outcomes for people with resectable locally advanced gastric or gastroesophageal junction cancer. About 49 participants will receive the c…
Matched conditions: GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Ting Liu • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Triple-Drug cocktail aims to wipe out stomach tumors before surgery
Disease control Not yet recruitingThis phase II trial tests whether adding an immunotherapy drug (retlirafusp alfa) and possibly a third drug (pertuzumab) to the targeted therapy trastuzumab rezetecan can completely eliminate tumors before surgery in people with locally advanced HER2-positive stomach or gastroeso…
Matched conditions: GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New drug combo aims to outperform immunotherapy in Hard-to-Treat stomach cancer
Disease control Not yet recruitingThis Phase 3 trial tests whether an experimental drug called QLS31905, combined with chemotherapy (CAPOX), works better than the current immunotherapy drug sintilimab plus the same chemotherapy for people with advanced gastric or gastroesophageal junction cancer. The study includ…
Matched conditions: GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New drug cocktail aims to shrink stomach tumors before surgery
Disease control Not yet recruitingThis early-phase trial is testing a combination of two drugs—trastuzumab rezetecan and retlirafusp alfa—in 12 people with HER2-positive stomach or gastroesophageal junction cancer. The treatment is given before surgery to see if it can safely shrink tumors. The main focus is on s…
Matched conditions: GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Stomach cancer hope: triple therapy may boost tumor clearance before surgery
Disease control Not yet recruitingThis phase II trial tests whether adding low-dose radiotherapy and the immunotherapy drug tislelizumab to standard chemotherapy can improve outcomes for people with locally advanced stomach or gastroesophageal junction cancer. About 114 participants will be randomly assigned to r…
Matched conditions: GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Jiangsu Cancer Institute & Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New Immunotherapy-Chemo cocktail targets stomach cancer
Disease control Not yet recruitingThis Phase II trial tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab, together called QL1706) plus chemotherapy for people with advanced HER2-negative stomach or gastroesophageal junction cancer. The study will enroll 64 participants who have not h…
Matched conditions: GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Drug cocktail aims to shrink stomach tumors before surgery in small trial
Disease control Not yet recruitingThis phase 2 trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab), a targeted therapy (lenvatinib), and chemotherapy (SOX) in 20 people with a specific type of advanced stomach or gastroesophageal junction cancer (MSI-H/dMMR). The goal is to see if …
Matched conditions: GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Jun 26, 2026 13:09 UTC